Fig. 3: Treatment efficacy in patients with or without LN involvement. | Signal Transduction and Targeted Therapy

Fig. 3: Treatment efficacy in patients with or without LN involvement.

From: CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients

Fig. 3

a, b Kaplan‒Meier curves showing EFS by CD8+ nTILs in patients with (a) or without (b) LN involvement. LN metastasis group number: 24; event number: 5; median follow-up: 33 months; no LN metastasis group number: 75; event number: 8; median follow-up (survivors): 26 months. HRs were not computed because of the low number of patients in the LN metastasis subgroups

Back to article page